๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Illinois
Clinical trial register · United States · industry-sponsored

Clinical Trials in Illinois, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9115 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 24 Sep 2026, 03:16 UTC
9115
Studies in scope
industry-sponsored, all four open statuses
4955
Recruiting now
open to new participants
2206
Lead sponsors
across recruiting studies
Top states
California 5299 Florida 4396 Illinois 2477 Georgia 2346 Arizona 2230
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Illinois

2477 of 9115 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772Irritable Bowel Syndrome, Constipation
Eli Lilly and Company
Phase 2
342
Arizona, California, Florida, Illinois, Indiana, Kentucky, New York, Ohio
2026-04-29
By invitation
Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
NCT07637162Fibromyalgia
Axsome Therapeutics, Inc.
Phase 3
300
Arkansas, California, Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana
2026-04-29
Recruiting
U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures
NCT07325578Bone Tumor, Osteoporosis, Traumatic Fracture
Precision IO Group
Not applicable
60
California, Florida, Illinois
2026-04-28
Recruiting
Phase 2 Study to Assess the Safety and Efficacy of ANG003
NCT07450547Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Anagram Therapeutics, Inc.
Phase 2
113
California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky, Maine
2026-04-24
Recruiting
52-week Open Label Safety-Tolerability Study
NCT07369154Schizophrenia
LB Pharmaceuticals Inc.
Phase 3
900
Arizona, Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri
2026-04-23
Recruiting
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
NCT07342478CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed
Newave Pharmaceutical Inc
Phase 3
306
Illinois, Maryland, Nevada, Ohio, Pennsylvania, Washington
2026-04-23
Active, closed
ATI Evidence-based Guide Investigating Medical and Preventative Services
NCT04050319Sport Medicine
ATI Holdings, LLC
Observational
550,000
Illinois
2026-04-23
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Arizona, California, Colorado, Florida, Illinois, Indiana, New York, Oregon
2026-04-23
Recruiting
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
NCT07596901Myasthenia Gravis, Generalized
Aurinia Pharmaceuticals Inc.
Phase 1/2
81
California, Florida, Illinois, Michigan, Texas
2026-04-22
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995Metastatic Castration-resistant Prostate Cancer
BioNTech SE
Phase 3
736
California, Colorado, Florida, Illinois, Maryland, New York, Ohio, Tennessee
2026-04-22
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232Crohn Disease
Janssen Research & Development, LLC
Phase 3
530
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2026-04-21
Active, closed
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
NCT07503210Obesity
Novo Nordisk A/S
Phase 3
606
Alabama, California, Florida, Illinois, Indiana, North Carolina, Pennsylvania, Rhode Island
2026-04-21
Recruiting
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
NCT07531095Small Cell Lung Cancer
Amgen
Phase 1
160
Arizona, Florida, Illinois, Minnesota, New York, Tennessee, Virginia
2026-04-21
Recruiting
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
NCT07489651Generalized Anxiety Disorder
Reunion Neuroscience Inc
Phase 2
64
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Michigan
2026-04-20
Recruiting
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
NCT07441876Achondroplasia
BioMarin Pharmaceutical
Phase 2/3
160
California, Delaware, Illinois, Maryland, Ohio, Pennsylvania, Texas
2026-04-20
Recruiting
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
NCT07464925Glioblastoma Multiforme of Brain, Glioma, Glioblastoma
Tetragon Biosciences Ltd
Phase 1
30
Florida, Illinois, New York
2026-04-20
Recruiting
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07509307Obesity, Overweight, Osteoarthritis, Knee
Novo Nordisk A/S
Phase 3
400
California, Connecticut, Florida, Illinois, Kentucky, Michigan, Missouri, New York
2026-04-20
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
NCT07415954Diabetes Mellitus, Type 2
Novo Nordisk A/S
Phase 2
270
California, Florida, Idaho, Illinois, Massachusetts, Missouri, North Carolina, Ohio
2026-04-17
Recruiting
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
NCT07286032Patients With Chemotherapy-Induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
150
California, Colorado, Florida, Illinois, New Jersey, New York
2026-04-16
Recruiting
Novel Stretching Device Versus Night Splints
NCT05216679Plantar Fasciitis
SAE Orthopedics
Not applicable
100
Illinois
2026-04-15
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
NCT07496567Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
EyeBiotech Ltd.
Phase 2/3
960
Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Kansas
2026-04-15
Recruiting
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
NCT07264959Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Observational
150
Colorado, Illinois, Maryland, Massachusetts, Michigan, Missouri, Utah
2026-04-15
Recruiting
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06769698Head and Neck Squamous Cell Carcinoma (HNSCC)
Regeneron Pharmaceuticals
Phase 2
120
California, Florida, Georgia, Illinois, Kentucky, Michigan, Nebraska, New York
2026-04-14
Recruiting
Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass
NCT07015424Weight Regain, Weight Loss
Boston Scientific Corporation
Not applicable
108
California, Florida, Illinois, Maryland, Minnesota, New York, Texas, West Virginia
2026-04-14
Recruiting
Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)
NCT07210515Complex Regional Pain Syndrome Type I
Ambros Therapeutics, Inc.
Phase 3
270
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2026-04-14
Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naรฏve and Biologic-naรฏve Systemic Lupus Erythematosus
NCT07430306Systemic Lupus Erythematosus
AstraZeneca
Phase 3
245
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-04-13
Recruiting
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
NCT06964087Type I Diabetes
Op-T LLC
Phase 2
72
Alabama, California, Colorado, Illinois, Washington
2026-04-10
Recruiting
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
NCT07519395Irritable Bowel Syndrome
GlaxoSmithKline
Phase 2
420
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-04-08
Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen
Phase 1
464
California, Illinois, Indiana, Maine, Tennessee, Texas
2026-04-08
Recruiting
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
NCT07424404Schizophrenia, Autism-Related Irritability
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-04-07
Active, closed
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
NCT07497880Obesity, Overweight
Kailera
Phase 2
306
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana
2026-04-06
Not yet open
Extensively Hydrolyzed Formula Growth Monitioring Study (GMS)
NCT07513506Growth
Mead Johnson Nutrition
Not applicable
214
Alabama, Arkansas, Florida, Illinois, Kentucky, North Carolina, Tennessee, Texas
2026-04-03
Recruiting
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
NCT07456696Post Traumatic Stress Disorder
Transcend Therapeutics
Phase 3
300
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Louisiana
2026-04-02
Recruiting
Achilles Tendinopathy Embolization
NCT07477860Achilles Tendinopathy (AT)
Joint & Vascular Institute
Phase 1
10
Illinois
2026-04-01
Recruiting
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
NCT07556159Asthma
Sanofi
Observational
2,500
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Montana
2026-04-01
Recruiting
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
NCT07459647Schizophrenia
MapLight Therapeutics
Phase 2
500
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2026-03-31
Recruiting
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
NCT07199465Cytomegalovirus Prophylaxis
Merck Sharp & Dohme LLC
Phase 1
40
Alabama, California, Colorado, Florida, Georgia, Illinois, Michigan, Minnesota
2026-03-30
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
EyeBiotech Ltd.
Phase 2/3
960
Arizona, Arkansas, California, Florida, Illinois, Indiana, Maryland, Michigan
2026-03-27
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Eli Lilly and Company
Phase 2
1,431
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2026-03-26
Recruiting
A Multi Center Study Testing a New Implant for Adults With Severe Emphysema
NCT07119229Emphysema or COPD, Emphysema, COPD
Pulmair Medical, Inc.
Not applicable
60
California, Illinois, Massachusetts
2026-03-25
Recruiting
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
NCT07363577Schizophrenia
LB Pharmaceuticals Inc.
Phase 3
456
Arkansas, California, Florida, Georgia, Illinois, Missouri, Ohio
2026-03-25
Recruiting
Transition to KPL-387 Monotherapy Dosing & Administration Study
NCT07288216Recurrent Pericarditis, Heart Diseases, Pericarditis
Kiniksa Pharmaceuticals International, plc
Phase 2
80
Arizona, California, Florida, Illinois, Maryland, Minnesota, New York, Ohio
2026-03-25
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
Boehringer Ingelheim
Phase 2
132
Alabama, California, Colorado, Florida, Illinois, Maryland, Michigan, New York
2026-03-23
Recruiting
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
NCT07532603Lichen Planopilaris
Priovant Therapeutics, Inc.
Phase 2/3
342
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2026-03-19
Recruiting
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07474792Plaque Psoriasis
Oruka Therapeutics, Inc.
Phase 2
160
Alabama, Arizona, California, Connecticut, Florida, Illinois, Massachusetts, Michigan
2026-03-19
By invitation
Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF)
NCT07286201Chronic Rhinosinusitis (CRS), Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Polyganics BV
Not applicable
110
Colorado, Georgia, Illinois, Louisiana, Maryland, South Carolina, Texas, Utah
2026-03-19
Recruiting
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
NCT07219459Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
CatalYm GmbH
Phase 2
104
California, Georgia, Illinois, Massachusetts
2026-03-19
Recruiting
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07154290Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
Regeneron Pharmaceuticals
Phase 2
300
Alabama, Arizona, California, District of Columbia, Florida, Illinois, Indiana, Maryland
2026-03-18
Recruiting
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT07387367Adenovirus Infections
SymBio Pharmaceuticals
Phase 3
180
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2026-03-17
Recruiting
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
NCT07473778HIV Infections
Gilead Sciences
Observational
3,000
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2026-03-17
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Alabama, Arizona, California, Connecticut, Georgia, Hawaii, Illinois, Kentucky
2026-03-16
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 3
850
Alabama, Arizona, Colorado, Delaware, Florida, Georgia, Illinois, Indiana
2026-03-16
Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
NCT07143019Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm
phenox Inc.
Not applicable
214
Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Massachusetts
2026-03-16
Recruiting
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
NCT07467993Schizophrenia
Novartis Pharmaceuticals
Phase 2
142
Arkansas, California, Florida, Georgia, Illinois, Missouri
2026-03-16
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb
Phase 1/2
198
California, Illinois, Michigan, New Jersey, New York, Oregon, Tennessee, Washington
2026-03-16
Recruiting
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
NCT07482176Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Adverum Biotechnologies, Inc.
Phase 3
284
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-03-16
Recruiting
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
NCT07470853PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
Whitehawk Therapeutics, Inc.
Phase 1
265
Arkansas, California, Florida, Illinois, Michigan, New York, North Carolina, Ohio
2026-03-15
By invitation
Long-Term Open-Label Extension Study of Oral Levosimendan
NCT07436689Pulmonary Hypertension Associated With HFpEF
Tenax Therapeutics, Inc.
Phase 3
800
Illinois, Massachusetts, Minnesota, Missouri, Nebraska, North Carolina, South Carolina, Wisconsin
2026-03-13
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb
Phase 2/3
690
Arizona, California, Florida, Georgia, Illinois, Iowa, Minnesota, Missouri
2026-03-13
Recruiting
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
NCT07412470Kidney Transplant Rejection
Sanofi
Phase 2/3
526
Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan, New York, Ohio
2026-03-13
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 โ‰ฅ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 3
750
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-03-12
Active, closed
How Fig Polyphenols Affect Blood Sugar and Insulin Levels After Eating in Adults at Risk for Diabetes
NCT07625046Pre Diabetic
Clinical Nutrition Research Center, Illinois Institute of Technology
Not applicable
5
Illinois
2026-03-12
Recruiting
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
NCT07475806Muscle-invasive Bladder Cancer
Astellas Pharma Global Development, Inc.
Phase 2
240
Arkansas, Illinois, Michigan, New Jersey, New York, Pennsylvania, South Carolina, Texas
2026-03-12
Active, closed
Evaluation of the Safety and Efficacy of Dehydrated Human Placenta Tissue (dHPT) for Wound Healing
NCT07375160Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU), Pressure Ulcer (PU)
Cellution Biologics
Observational
300
Illinois
2026-03-12
Recruiting
Phase 3 Pivotal Trial Comparing CARTISTEMยฎ and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis
NCT07339111Knee Cartilage Defects
Medipost, Inc.
Phase 3
300
Alabama, Arizona, California, Colorado, Illinois, Kentucky, Louisiana, Michigan
2026-03-11
Recruiting
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma
Pfizer
Phase 1/2
132
Arkansas, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2026-03-11
Recruiting
Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)
NCT07277582Long QT Syndrome (LQTS) 2
Thryv Therapeutics, Inc.
Phase 2/3
84
Arizona, California, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina
2026-03-07
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
Janssen Research & Development, LLC
Phase 3
600
California, Florida, Georgia, Illinois, Louisiana, Michigan, New Jersey, North Carolina
2026-03-05
Active, closed
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
NCT07458269Obesity
Kailera
Phase 2
264
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-03-04
Recruiting
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
NCT07221838Generalized Myasthenia Gravis, gMG
Alexion Pharmaceuticals, Inc.
Phase 4
75
Illinois, New Jersey, North Carolina, Tennessee
2026-03-04
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
Tenax Therapeutics, Inc.
Phase 3
540
Alabama, Arizona, California, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2026-03-03
Recruiting
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
NCT07615426Schizophrenia
Janssen Research & Development, LLC
Phase 1
64
California, Georgia, Illinois, Michigan, New York, Texas
2026-03-02
Not yet open
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
NCT07328529Aggressive Behavior in Fragile X Syndome
Azevan Pharmaceuticals
Phase 2
80
California, Illinois, Ohio
2026-03
Recruiting
COPD Exacerbation Follow Up
NCT07118306COPD (Chronic Obstructive Pulmonary Disease)
Viz.ai, Inc.
Observational
485
Illinois, New Jersey, Pennsylvania, Virginia, Wisconsin
2026-02-27
Recruiting
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCT07379827Schizophrenia
Bristol-Myers Squibb
Observational
1,500
Arkansas, California, Florida, Georgia, Illinois, Michigan, Minnesota, Nebraska
2026-02-26
Recruiting
Phase 3 Study of Telitacicept in Active Primary Sjรถgren's Disease
NCT07404865Primary Sjogren's Disease
Vor Biopharma
Phase 3
250
Arizona, California, Colorado, Florida, Idaho, Illinois, Louisiana, Maryland
2026-02-26
Active, closed
Intravascular Neuro OCT Imaging System for Aneurysm Treatment Evaluation
NCT07214220Intracranial Aneurysm
Spryte Medical
Not applicable
67
Florida, Illinois, Massachusetts, New York
2026-02-25
Recruiting
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
NCT07339423Obesity
Novo Nordisk A/S
Phase 3
1,150
Florida, Georgia, Illinois, Indiana, Missouri, New York, North Carolina, Pennsylvania
2026-02-24
Active, closed
ATI Evidence-based Guide Investigating Clinical Services
NCT02285868Primary Body Region (Arranged Most Common to Least), Lumbar/SI, Knee, Shoulder
ATI Holdings, LLC
Observational
4,000,000
Illinois
2026-02-24
Recruiting
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
NCT07449702Plaque Psoriasis
Oruka Therapeutics, Inc.
Phase 2
240
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Maryland, Massachusetts
2026-02-23
Recruiting
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
NCT07484217Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Axsome Therapeutics, Inc.
Phase 3
508
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada
2026-02-23
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
AstraZeneca
Phase 3
508
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-02-23
Recruiting
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
NCT07425574Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Astellas Pharma Global Development, Inc.
Observational
90
Arizona, California, Florida, Illinois, Michigan, Mississippi, North Carolina, Ohio
2026-02-20
Active, closed
A Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth
NCT07588243Androgenic Alopecia
CynosureLutronic
Not applicable
44
Illinois, Massachusetts
2026-02-19
Recruiting
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07435428Moderate to Severe Glabellar Lines
Ipsen
Phase 3
1,300
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana
2026-02-18
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558Ovarian Neoplasms, Ovarian Cancer
Merck Sharp & Dohme LLC
Phase 3
900
Alabama, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maine
2026-02-16
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
Boehringer Ingelheim
Phase 3
286
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2026-02-16
Active, closed
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
EyePoint Pharmaceuticals, Inc.
Phase 3
240
California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Louisiana
2026-02-16
Recruiting
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
NCT07285018Diabetic Peripheral Neuropathic Pain
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-02-16
Recruiting
Aspiration Thrombectomy Using the Symphony or Prodigy System
NCT07350499Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
Imperative Care, Inc.
Observational
750
Alabama, Florida, Illinois, Indiana, New York, Ohio, Virginia
2026-02-13
Recruiting
A Study of Brenipatide in Participants With Opioid Use Disorder
NCT07420283Opioid Use Disorder
Eli Lilly and Company
Phase 2
465
Arizona, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maryland
2026-02-13
Recruiting
A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07491458MASH - Metabolic Dysfunction-Associated Steatohepatitis
Rivus Pharmaceuticals, Inc.
Phase 2
180
Arizona, Arkansas, California, Florida, Illinois, Louisiana, Michigan, Minnesota
2026-02-13
Recruiting
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07210723Symptomatic Genetic Dilated Cardiomyopathy
Kardigan, Inc.
Phase 2/3
332
Alabama, California, District of Columbia, Florida, Illinois, Louisiana, Maryland, Massachusetts
2026-02-13
Recruiting
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
NCT07197944Short Bowel Syndrome
Zealand Pharma
Phase 3
90
Illinois, Missouri, Nebraska, New York, Tennessee
2026-02-11
Recruiting
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
NCT07285785Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea
Bausch Health Americas, Inc.
Phase 4
54
California, Florida, Georgia, Illinois, Oregon, Texas, Virginia
2026-02-11
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naรฏve Persons With HIV-1 (INNOVATE Study)
NCT07202546HIV Infections
ViiV Healthcare
Phase 2
186
California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky, Missouri
2026-02-11
Active, closed
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related Cataract
NCT07395986Age Related Cataracts
Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.
Phase 2
8
Arizona, California, Colorado, Florida, Georgia, Illinois, North Carolina, North Dakota
2026-02-10
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
Eli Lilly and Company
Phase 3
900
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-02-10
Rows per page Showing 201–300 of 2477
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-usa/state/illinois?page=3

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,115 studies in total at the last sync on 24 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,477 of those studies with a site in Illinois.

How many clinical trials are recruiting in Illinois?

1,260 of the 2,477 studies on this page are recruiting new participants as of the 24 Sep 2026, 03:16 UTC sync. A further 37 have not yet opened recruitment, 1,117 are active but closed to new participants, and 63 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.